Policy Snapshot
December 15, 2023
Showing 11 - 20 of 105 results
Policy Snapshot
May 31, 2024
Morbidity and Mortality Weekly Report — Early Safety Findings Among Persons Aged 60 Years and Older Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024
A new Morbidity and Mortality Weekly Report (MMWR) highlights safety findings for two respiratory syncytial virus (RSV) vaccines licensed by the Food and Drug Administration (FDA) in May 2023 for adults 60 years of age and older.
PALTmed In The News
August 23, 2024
New COVID vaccines available, but payment issues complicate access for nursing homes
Two new COVID vaccines were approved for use late last week, and experts continue to encourage seniors to get the booster, but payment issues for nursing homes and long-term care pharmacies complicate access for residents.
Spotlight
September 8, 2025
COVID Vaccine Update (September 2025)
An update on the current approval status of COVID-19 vaccines, what it means for patients, pharmacies, and healthcare teams, and how PALTmed is supporting post-acute and long-term care providers during respiratory virus season.
JAMDA
July 20, 2021
Racial Disparities in COVID-19 Vaccine Acceptance: Building Trust to Protect Nursing Home Staff and Residents
Vaccines are critical to protect both nursing home residents and staff from COVID-19, but some staff have expressed reservations about being vaccinated. In this brief report, we describe interventions that Genesis HealthCare—one of the largest US long-term care providers—implemented after recognizing midwa...
Sponsored Education
Feb 18, 2026 12:00 pm - Feb 18, 2026 1:00 pm
Stronger Shields for Seniors: Respiratory Protection with High-Dose Flu and Recombinant Protein non-mRNA COVID Vaccine Strategies
This webinar will explore evidence-based approaches to protecting respiratory health in LTC settings, with a focus on high dose influenza vaccine and a recombinant protein, non-mRNA COVID-19 vaccine option. Sanofi’s medical directors, Dr. Morgan Anderson and Dr. Katie Sharff, will share insights on the latest influenza vaccine pooled analysis FLUNITY-HD and discuss evolving data on the recombinant protein, non-mRNA COVID-19 vaccine. They will be joined by Dr. Chad Worz, CEO of the American Society of Consultant Pharmacists (ASCP), to provide expert perspectives on clinical implications and practical applications for elder care.
Read More
JAMDA
February 15, 2019
Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season
Influenza is a leading cause of admissions for nursing home (NH) residents. We previously evaluated the effectiveness of a high-dose trivalent influenza vaccine (HD) compared to a standard-dose influenza vaccine (SD) through a cluster-randomized trial of NH residents. Fewer residents from facilities rando...
JAMDA
March 20, 2021
“Somebody Like Me”: Understanding COVID-19 Vaccine Hesitancy among Staff in Skilled Nursing Facilities
The vaccination of skilled nursing facility (SNF) staff is a critical component in the battle against COVID-19. Together, residents and staff constitute the single most vulnerable population in the pandemic. The health of these workers is completely entangled with the health of those they care for. Vaccina...
JAMDA
May 30, 2025
Which Enhanced Influenza Vaccine Has the Greatest Immunogenicity in Long-Term Care Residents: The Adjuvanted or the High-Dose Formulation?
This study compares enhanced influenza vaccines recommended for older adults, adjuvanted flu vaccine (aTIV, FLUAD) vs high-dose flu vaccine (HD-IIV3, FLUZONE HD) to determine if they met noninferiority standards for older long-term care facility (LTCF) residents.
JAMDA
June 7, 2023
Association of Sources of COVID-19 Information with Vaccine Uptake, Preventive Behaviors, and Perceived Severity of COVID-19
To investigate the association of using informal sources and reliance on multiple sources of information with actual COVID-19 vaccine uptake, the number of doses of vaccine received, COVID-19 testing, essential preventive measures, and perceived severity of COVID-19.
